Pefloxacin is a systemic antibacterial agent commonly used to help manage conditions involving inflammatory or irritative processes. The medicine is utilized in contexts involving heightened systemic burden, particularly when managing conditions marked by increased physiological stress where supportive symptom management is appropriate. The core benefit is its role in managing conditions, which contributes to easing the overall symptom load.

The medication is applied in clinical settings for conditions presenting with acute episodes and systemic imbalance, including those involving significant symptom expression, and for conditions marked by heightened symptoms. It is relevant for easing symptoms associated with complicated genitourinary tract conditions (like pyelonephritis and prostatitis), bone-related conditions, and serious skin and soft tissue manifestations.

“Its supportive role helps address symptom clusters that create noticeable physiological strain.”

Quick Fact: Symptom Support for Discomfort and Systemic Imbalance
Primary Symptom Domain	Symptoms related to systemic imbalance (e.g., high fever) and inflammatory states (e.g., localized pain).
Contextual Benefit	Assists with maintaining functional stability during difficult episodes marked by heightened distress.
Target Conditions	Applied in conditions characterized by periods of heightened symptoms, such as conditions involving inflammatory or irritative processes.

Regulatory References

1. European Medicines Agency (EMA) review of fluoroquinolones

Official Eligibility Rules for Pefloxacin

Pefloxacin is a restricted-use antibacterial strictly governed by population-specific eligibility rules detailed in regulatory prescribing information. Eligibility is primarily limited to adult patients who do not present with specific contraindications, which largely reflect the documented risk profile of the fluoroquinolone class.

---

Absolute Contraindications

Population Group	Restriction Status	Regulatory Rationale (Eligibility)
Age (Pediatric/Adolescent)	Contraindicated	Until skeletal growth is complete (risk of severe joint disorders).
Reproductive Status	Contraindicated	Prohibited during pregnancy and lactation (breastfeeding).
Hypersensitivity	Contraindicated	History of allergy to Pefloxacin or any quinolone/fluoroquinolone.
Tendon History	Contraindicated	History of tendon damage related to previous quinolone use.

---

Conditional and Restricted Use

Use requires special caution or dose adjustment for specific populations, as mandated by health authorities:

• Older Adults (over 60 years): Increased risk of tendon rupture and QT interval prolongation.
• Organ Impairment: Patients with severe hepatic impairment or renal impairment require caution and dose modification.
• Comorbidities: Caution is required for patients with CNS disorders (e.g., seizure history), aortic aneurysm/dissection, or those receiving systemic corticosteroids (due to tendon risk).

Interactions with other medicines and products

The official regulatory profile for Pefloxacin is defined by specific interaction patterns that lead to altered drug exposure or augmented physiological effects.

Absorption-Reducing Interactions: Co-administration with multivalent cation-containing products, such as Iron salts, Zinc salts, and Antacids (containing aluminum or magnesium), causes a pharmacokinetic interaction resulting in reduced digestive absorption of Pefloxacin. Other products like Didanosine (DDI) and Strontium have a similar effect. To mitigate this reduced exposure, regulatory documentation specifies that these substances must be separated from Pefloxacin administration by more than 2 hours.

Drug Exposure Modification: Pefloxacin is documented to modify the clearance of other medicines. Co-administration with Theophylline results in increased plasma levels of Theophylline. Similarly, Pefloxacin increases the levels of co-administered Cyclosporine. Conversely, medicines such as Cimetidine and Probenecid are noted to increase Pefloxacin's own plasma levels.

Pharmacodynamic Augmentation: A critical pharmacodynamic interaction involves Antivitamins K (e.g., Warfarin), where Pefloxacin increases the anticoagulant effect, raising the risk of bleeding. This outcome necessitates monitoring of the International Normalized Ratio (INR). Furthermore, combinations with neuroexcitatory agents like NSAIDs or Foscarnet may increase the risk of seizures or heightened neuroexcitatory activities.

Inhibiting Key Bacterial Chromosome Management Enzymes

Pefloxacin is an enzyme inhibitor that targets DNA Gyrase (Topoisomerase II) and Topoisomerase IV, which are necessary for bacterial DNA structure and replication. By binding to these enzymes and stabilizing the enzyme-DNA intermediate (cleavable complex), the drug prevents the necessary resealing of DNA strands, initiating a cascade of genetic failure within the pathogen.

---

Triggering the Lethal Bactericidal Cascade

This molecular inhibition leads directly to the accumulation of irreversible double-strand DNA breaks and the activation of a futile SOS repair response. This lethal process results in the rapid, non-reversible death of the bacterial cell (bactericidal effect), establishing a mechanism that supports the reduction of microbial populations.

---

️ Constraints on Mechanism Efficacy

The drug's mechanism can be limited by two biological constraints: acquired mutations in the target genes (gyrA and parC) that reduce Pefloxacin's binding affinity, and the increased activity of bacterial efflux pumps that actively expel the drug from the cell. These factors reduce the drug's effective concentration at its target, resulting in diminished stabilization of the cleavable complex and a constrained bactericidal effect.

How to Use Pefloxacin

Administration Routes and Standard Dosing

Pefloxacin is administered through two approved routes: the oral route using film-coated tablets and the intravenous (IV) route using a sterile solution for infusion. The standard maintenance regimen for adults is 400 mg twice daily (b.i.d.). For situations requiring rapid plasma concentrations, an initial loading dose of 800 mg may be administered as a single dose. A single 800 mg dose may also be specified for treating certain acute, uncomplicated conditions.

---

Contextual Use and Dosing Adjustments

Administration is subject to specific procedural conditions established for the drug. Oral tablets are taken with food or immediately after a full meal to help mitigate potential gastrointestinal discomfort. The IV infusion is prepared with the appropriate diluent, typically 5% dextrose solution, and is administered as a slow infusion over a period of at least 60 minutes.

Dosing involves modification for certain populations. For older adults (over 65 years), a reduced regimen, such as 400 mg once daily or 200 mg twice daily, is often recommended. For patients with significant hepatic impairment, the dosing interval is increased (e.g., to once daily, every 36 hours, or every 48 hours), depending on the degree of liver dysfunction. Pefloxacin is not recommended for use in children or growing adolescents.

---

Duration and Form Handling

Treatment duration typically ranges from 5 to 10 days, although extended courses are specified for severe chronic conditions; for example, up to 14 days for chronic prostatitis, up to 6 months for endocarditis, and up to one year for chronic osteomyelitis. Oral tablets are swallowed whole and are not to be crushed or broken. Furthermore, administration is separated from antacids, iron, or zinc salts to prevent reduced systemic absorption.

Recent Clinical Evidence Overview

Pefloxacin is a synthetic broad-spectrum fluoroquinolone antibiotic used for the treatment of various bacterial infections. Clinical studies have explored its effectiveness across several infection types, including enteric fever and acute infectious diarrhea, often achieving high rates of bacteriological eradication.

Efficacy and Treatment Protocols

Research has examined different treatment durations for specific infections. For enteric fever, trials have evaluated short-course regimens (e.g., 5- to 7-day protocols), reporting high clinical cure rates. A study comparing 5-day versus 7-day pefloxacin treatment for enteric fever found similar clinical and bacteriological outcomes between the two protocols, suggesting that shorter courses may be feasible for certain patients. Similarly, in acute infectious diarrhea, both 5-day and 7-day protocols demonstrated clinical improvement and bacteriological eradication significantly different from control groups receiving symptomatic treatment.

Safety and Long-term Considerations

As a member of the fluoroquinolone class, Pefloxacin is associated with potential adverse effects that have been the subject of regulatory reviews and ongoing research. Common side effects reported in trials include gastrointestinal discomfort (nausea, vomiting, diarrhea) and central nervous system effects (headache, dizziness, insomnia).

Less frequent but more serious risks are noted, particularly affecting the musculoskeletal and nervous systems. These risks include tendinitis and tendon rupture, especially in older adults and those co-administered corticosteroids. Patients may also experience photosensitivity. The potential for QTc interval prolongation (an effect on the heart's electrical activity) is also a known consideration across the fluoroquinolone class, requiring caution, particularly with co-administered medications that share this risk.

Key Studies & References

1. Fluoroquinolone-Associated Tendinopathy: A Systematic Review and Meta-analysis
2. Fluoroquinolone Antimicrobials: Drug Class Review

Common questions about Пефлоксацин (FAQ)

---

Q: What kind of infections is Пефлоксацин typically prescribed to treat?

According to official product information, Pefloxacin is indicated for treating specific types of bacterial infections. These typically include complicated infections of the urinary tract and chronic infections like prostatitis, as well as certain infections of the respiratory system, bone, and joints.

---

Q: Is Пефлоксацин considered a broad-spectrum antibiotic?

Regulatory classification confirms that Pefloxacin is categorized as a broad-spectrum fluoroquinolone antibacterial agent. This classification describes its activity against a wide range of different types of susceptible bacteria.

---

Q: What are the signs of an allergic reaction to Пефлоксацин?

Regulatory documents describe serious hypersensitivity reactions that may occur with this medicine. Signs can include skin reactions such as rash, pruritus (severe itching), or urticaria (hives). In rare cases, regulatory documents note the possibility of a severe reaction known as anaphylactic shock.

---

Q: Can taking Пефлоксацин lead to a yeast infection?

Official side effect profiles note that antibiotics like Pefloxacin can sometimes cause a secondary infection. These are called superinfections, and one possible adverse reaction listed is candidiasis, which is a common type of yeast or fungal infection.

---

Q: Does Пефлоксацин interact with caffeine or coffee?

Pefloxacin is officially described as modifying the body's metabolism of Theophylline, a medication that is chemically related to caffeine. While specific regulatory guidance on caffeine is not always provided, official information reports an effect on related compounds.

---

Q: Should I avoid dairy products or fortified foods when taking Пефлоксацин?

Official information indicates that Pefloxacin absorption can be reduced when taken with products containing multivalent cations like calcium and magnesium. The need for separation from the drug is based on the potential for reduced absorption.

---

Q: Do vitamins or mineral supplements interfere with Пефлоксацин absorption?

Yes, official drug interaction documentation states that the body’s absorption of Pefloxacin is reduced by co-administration with supplements containing iron, zinc, and other multivalent cations. Official guidance describes mitigation strategies for reduced absorption, which often involve separating the administration of Pefloxacin from these supplements.

---

Q: What happens if I miss a dose of Пефлоксацин?

Official prescribing information contains general protocols for a missed dose, typically involving taking the dose when remembered, unless it is close to the time for the next scheduled dose.

---

Q: Does having diabetes affect the use of Пефлоксацин?

Official regulatory warnings for this class of antibiotics note a risk of dysglycaemia, which means abnormal blood sugar levels. This effect includes the possibility of both hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar) in patients with diabetes.

---

Q: Is there a known risk of liver damage associated with Пефлоксацин?

Official labeling reports that some patients experience elevated liver enzymes, known as transaminases, which can indicate liver strain. Furthermore, in rare cases, liver injury or hepatitis has been noted in patients receiving Pefloxacin.

---

Q: How does the body process and eliminate Пефлоксацин?

Pharmacokinetic data from official sources describe the drug's journey through the body. Pefloxacin is primarily metabolized (broken down) in the liver. It is then eliminated from the body through both the kidneys (renal) and non-renal routes.

---

Q: Why is hydration often emphasized when taking this type of antibiotic?

Pefloxacin is eliminated partially through the kidneys, as confirmed by regulatory pharmacokinetic data. Official guidance supports the importance of adequate hydration, as the drug is partially cleared by the kidneys, which is essential for proper drug clearance.

---

Q: Is there a large body of clinical research supporting the use of Пефлоксацин?

The clinical efficacy of Pefloxacin is supported by data from controlled trials and studies described in official sources. These studies examine the drug's effectiveness, including bacteriological eradication rates, in various indicated infections.

---

Q: Are there any specific food items that must be completely avoided with this medicine?

Official documentation notes that products containing polyvalent cations, such as certain mineral supplements and antacids, reduce absorption and must be separated from the drug. This is the main regulatory concern related to oral intake items that interfere with the drug's effectiveness.

---

Q: Why do doctors check my medical history carefully before prescribing Пефлоксацин?

Official warnings require careful assessment of patient history before prescribing this drug. This precaution is necessary to screen for pre-existing conditions, particularly concerning tendon disorders, nervous system conditions, and the risk of heart rhythm issues (QT prolongation).

---

Q: Can Пефлоксацин make me feel tired or drowsy?

Although official labeling may not explicitly list 'tired' or 'drowsy,' it does list common Central Nervous System (CNS) effects. These effects include headache, dizziness, and insomnia, which can indirectly contribute to generalized fatigue.

---

Q: What should I know about driving or operating machinery while on Пефлоксацин?

Official labeling addresses this directly, stating that the reported Central Nervous System (CNS) side effects may impair a person's abilities. Specifically, dizziness or visual disturbances may reduce the ability to drive or operate complex machinery safely.

---

Q: Is there a high risk of drug resistance developing with Пефлоксацин?

Regulatory information notes that bacterial resistance may develop through certain mechanisms. These include genetic changes (mutations) at the drug's target site and the action of efflux pumps that actively remove the drug from the bacterial cell, thus reducing its efficacy.

---

Q: Why is it important to complete the entire course of Пефлоксацин, even if I feel better?

Patient information materials describe the risks associated with premature cessation of the antibiotic course, which include the potential for the return of the original infection and the development of bacterial resistance.

Pefloxacin must be stored according to strict regulatory conditions to maintain its effectiveness and stability.

Official Storage Requirements

Storage Condition	Requirement
Temperature	Store not above 30 C or at room temperature.
Protection	Keep in a dry, well-ventilated place, protected from light and moisture.
Packaging	Must remain in its original container or blister pack, kept tightly closed.
Safety	Store out of the sight and reach of children.

Disposal Instructions

Any unused or expired Pefloxacin product must be handled and disposed of in accordance with local regulatory requirements. The safest method is utilizing a drug take-back program or an authorized collector. If a take-back option is unavailable and the medicine is not on the FDA's flush list, it may be disposed of in household trash by mixing it with an undesirable substance (e.g., dirt or used coffee grounds) and sealing it in a container before discarding. Environmental regulations require precautions to avoid discharge into drains or water courses.